We report several findings of immediate translational value for SCLC: 1) derivation of an SCLC-specific hub network (SSHN) that classifies SCLC from other lung cancers, including the closely related neuroendocrine tumors; 2) validation of the SSHN classifier across many data types, including expression microarrays from multiple platforms, RNAseq and shotgun proteomics; 3) co-varied expression of 2 oncogenes, SYK and FYN, in a subset of SCLC tumors and cell lines; and 4) identification of SYK as a candidate biomarker and therapeutic target for SCLC. Here, FYN is linked to lung cancer.